10 products found
AstraZeneca Products
-
Oncology
-
Model AZD0466 Phase I - haematological malignancies
Mechanism: BCL2/xL; Area under investigation: haematological malignancies; Date commenced phase: Q4 2019; Estimated Filing Acceptance: US: EU: Japan: China; Additional information: Partnered product. Molecule size: Small molecule; Status ...
-
Model AZD1390 Phase I - Glioblastoma
Mechanism: ATM inhibitor; Area under investigation: glioblastoma; Date commenced phase: Q2 2018; Estimated Filing Acceptance: US: EU: Japan: China. Additional information. Molecule size: Small molecule Status ...
-
Model AZD4573 Phase I - Haematalogical malignancies
Mechanism: CDK9 inhibitor Area under investigation: haematalogical malignancies Date commenced phase: Q4 2017 Estimated Filing Acceptance: US: EU: Japan: China. Additional information. Molecule size: Small molecule Status change: New to Phase ...
-
Cardiovascular, Renal & Metabolism
-
Model AZD2373 Phase I - Nephropathy
Mechanism: Podocyte health; Area under investigation: nephropathy; Date commenced phase: Q1 2020; Estimated Filing Acceptance: US: EU: Japan: China. Additional information. Molecule size: Small molecule; Status ...
-
Model AZD2693 - Phase I - NASH
Mechanism: NASH resolution; Area under investigation: NASH; Date commenced phase: Q4 2019; Estimated Filing Acceptance: US: EU: Japan: China. Additional information. Molecule size: Small molecule; Status ...
-
Model AZD3366 - Phase I - Cardiovascular Disease
Mechanism: CD39L3. Area under investigation: cardiovascular disease. Date commenced phase: Q4 2020. Estimated Filing Acceptance: Country:US, EU, Japan, China, Additional information: Molecule size: Small molecule. Status ...
-
Respiratory & Immunology
-
Model AZD4604 - Phase I - Asthma
Mechanism: Inhaled JAK1 inhibitor, Area under investigation:asthma, Date commenced phase: Q4 2021, Estimated Filing Acceptance: Country: US: EU: Japan: China. Additional information: Molecule size: Small molecule Status ...
-
Model AZD5055 - Phase I - Idiopathic Pulmonary Fibrosis
Mechanism: Porcupine inhibitor. Area under investigation: idiopathic pulmonary fibrosis. Date commenced phase: Q4 2021. Estimated Filing Acceptance: Country US: EU: Japan: China. Additional information: Molecule size: Small molecule. Status ...
-
Model AZD8630 - Phase I - Asthma
Mechanism: Inhaled TSLP Fab. Area under investigation: asthma. Date commenced phase: Q1 2022. Estimated Filing Acceptance: Country US:EU: Japan: China: Additional information: Partnered product. Molecule size: Large molecule. Status ...
-
Model ZD1402 - Phase II - Asthma
Mechanism: Inhaled IL-4Ra. Area under investigation: asthma. Date commenced phase: Q2 2021. Estimated Filing Acceptance: Country US: EU: Japan:China: Additional information: Partnered product. Status ...